CWP232291治疗复发或难治性急性髓系白血病及骨髓增生异常综合征的1期研究
这项首次人体、开放标签、剂量递增1期研究纳入69例血液系统恶性肿瘤患者(急性髓系白血病64例、骨髓增生异常综合征5例),CWP232291每日静脉给药7天、每21天重复,确定最大耐受剂量为257 mg/m2,最常见治疗中出现不良事件为恶心(64%)、呕吐(46%)、腹泻(36%)和输注相关反应(29%),54例可评估急性髓系白血病患者中1例完全缓解、1例部分缓解。
要点
- CWP232291最大耐受剂量为257 mg/m2,剂量限制性毒性包括恶心3例及腹痛、过敏反应、肌痛、皮疹各1例。
- 最常见治疗中出现不良事件为恶心44例(64%)、呕吐32例(46%)、腹泻25例(36%)、输注相关反应20例(29%)。
- 54例可评估急性髓系白血病患者中,153 mg/m2剂量1例完全缓解、198 mg/m2剂量1例部分缓解。
核心结论
- CWP232291在复发或难治性急性髓系白血病及骨髓增生异常综合征患者中最大耐受剂量为257 mg/m2,初步显示有限疗效。
- 未来研究将探索CWP232291作为联合治疗,其作用机制旨在通过Wnt通路阻断清除更早期祖细胞。
研究设计与样本
- 首次人体、开放标签、剂量递增1期研究,采用改良3+3设计,设15个剂量递增队列(4至334 mg/m2)和1个剂量扩展队列。
- 共纳入69例血液系统恶性肿瘤患者,其中急性髓系白血病64例、骨髓增生异常综合征5例。
- CWP232291每日静脉给药,连续7天,每21天重复。
主要发现
- 最常见治疗中出现不良事件为恶心44例(64%)、呕吐32例(46%)、腹泻25例(36%)、输注相关反应20例(29%)。
- ≥3级治疗中出现不良事件中,肺炎8例(12%);低磷血症6例(8%);白细胞增多、恶心、蜂窝织炎、脓毒症、低钾血症各5例(各7%);高血压4例(6%)。
- 剂量限制性毒性包括恶心3例,腹痛、过敏反应、肌痛、皮疹各1例;最大耐受剂量定义为257 mg/m2。
- CWP232204(CWP232291活性代谢物)在第1天和第7天均显示药代动力学线性,终末半衰期约12小时。
- 54例可评估急性髓系白血病患者中,153 mg/m2剂量1例完全缓解、198 mg/m2剂量1例部分缓解;两例骨髓原始细胞百分比分别从58.3%降至3.5%、从15.0%降至4.2%。
关键数值与推荐
- 最大耐受剂量定义为257 mg/m2。
- 剂量限制性毒性:恶心3例;腹痛、过敏反应、肌痛、皮疹各1例。
- 54例可评估急性髓系白血病患者中,153 mg/m2剂量1例完全缓解,198 mg/m2剂量1例部分缓解。
- 骨髓原始细胞百分比:完全缓解者从58.3%降至3.5%,部分缓解者从15.0%降至4.2%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CWP232291 (CWP291) is a small-molecule inhibitor of Wnt signaling that causes degradation of β-catenin via apoptosis induction through endoplasmic reticulum stress activation. This first-in-human, open-label, dose-escalation study to evaluate the safety, maximum tolerated dose (MTD), and preliminary efficacy of CWP291 enrolled 69 patients with hematologic malignancies (acute myeloid leukemia [AML], n = 64; myelodysplastic syndrome, n = 5) in 15 dose-escalation cohorts of 4 to 334 mg/m2 using a modified 3+3 design and 1 dose-expansion cohort. CWP291 was administered IV daily for 7 days every 21 days. The most common treatment-emergent adverse events (TEAEs) were nausea (n = 44, 64%), vomiting (n = 32, 46%), diarrhea (n = 25, 36%), and infusion-related reactions (n = 20, 29%). Grade ≥3 TEAEs in >3 patients (5%) were pneumonia (n = 8, 12%); hypophosphatemia (n = 6, 8%); leukocytosis, nausea, cellulitis, sepsis, and hypokalemia (n = 5 each, 7% each); and hypertension (n = 4, 6%). Dose-limiting toxicities included nausea (n = 3) and abdominal pain, anaphylactic reaction, myalgia, and rash (n = 1, each); the MTD was defined at 257 mg/m2. CWP232204, the active metabolite of CWP291, showed pharmacokinetic linearity on both days 1 and 7, and a terminal half-life of ∼12 hours. Among 54 response-evaluable AML patients, there was one complete response at a dose of 153 mg/m2 and one partial response at 198 mg/m2; bone marrow blast percentage reduced from a median of 58.3% to 3.5% and 15.0% to 4.2%, respectively. Future studies will explore CWP291, with a mechanism of action aimed at eradication of earlier progenitors via Wnt pathway blockade, as combination therapy. This trial was registered at www.clinicaltrials.gov as #NCT01398462.
引用
- Lee JH, Faderl S, Pagel JM, et al. Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. Blood Adv. 2020. PMID: 32396615. doi:10.1182/bloodadvances.2019000757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。